{"id":303313,"date":"2026-10-13T09:05:46","date_gmt":"2026-10-13T03:35:46","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=303313"},"modified":"2026-10-13T09:05:46","modified_gmt":"2026-10-13T03:35:46","slug":"kilitch-drugs-vs-sudarshan-pharma-vs-chandan-healthcare","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/kilitch-drugs-vs-sudarshan-pharma-vs-chandan-healthcare\/","title":{"rendered":"Kilitch Drugs vs Sudarshan Pharma vs Chandan Healthcare: Which Stock Should You Track"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Kilitch Drugs (India) PE 29.19, mkt cap Rs 852 crore. Sudarshan Pharma Industries PE 35.15, mkt cap Rs 878 crore. Chandan Healthcare PE 23.06, mkt cap Rs 581 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare is a side-by-side comparison of three companies from the pharma and healthcare space. On this comparison, Kilitch Drugs (India) carries a market capitalisation of about Rs 852 crore, against Rs 878 crore for Sudarshan Pharma Industries and Rs 581 crore for Chandan Healthcare, with return on equity of 10.79%, 15.03% and 11.34% respectively. Each company&#8217;s numbers are presented here without a declared preference, since the right stock depends on an investor&#8217;s own criteria.<\/p>\n<\/div>\n<p>Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare starts with the core numbers most investors compare within the pharma and healthcare segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.<\/p>\n<p>All three names sit in the pharma and healthcare bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=kilitch-drugs-vs-sudarshan-pharma-vs-chandan-healthcare\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/kilitch-drugs-vs-sudarshan-pharma-vs-chandan-healthcare\/#Kilitch_Drugs_India_Sudarshan_Pharma_Industries_and_Chandan_Healthcare_Company_Overview\" title=\"Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare: Company Overview\">Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare: Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/kilitch-drugs-vs-sudarshan-pharma-vs-chandan-healthcare\/#Kilitch_Drugs_India_vs_Sudarshan_Pharma_Industries_vs_Chandan_Healthcare_Valuation_and_Profitability_Snapshot\" title=\"Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare: Valuation and Profitability Snapshot\">Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare: Valuation and Profitability Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/kilitch-drugs-vs-sudarshan-pharma-vs-chandan-healthcare\/#Kilitch_Drugs_India_vs_Sudarshan_Pharma_Industries_vs_Chandan_Healthcare_Latest_Quarterly_Results\" title=\"Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare: Latest Quarterly Results\">Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare: Latest Quarterly Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/kilitch-drugs-vs-sudarshan-pharma-vs-chandan-healthcare\/#Kilitch_Drugs_India_vs_Sudarshan_Pharma_Industries_vs_Chandan_Healthcare_Five-Quarter_Revenue_and_Net_Profit_Trend\" title=\"Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare: Five-Quarter Revenue and Net Profit Trend\">Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare: Five-Quarter Revenue and Net Profit Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/kilitch-drugs-vs-sudarshan-pharma-vs-chandan-healthcare\/#What_Should_Investors_Look_at_Beyond_These_Numbers\" title=\"What Should Investors Look at Beyond These Numbers?\">What Should Investors Look at Beyond These Numbers?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/kilitch-drugs-vs-sudarshan-pharma-vs-chandan-healthcare\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/kilitch-drugs-vs-sudarshan-pharma-vs-chandan-healthcare\/#FAQs_on_Kilitch_Drugs_India_vs_Sudarshan_Pharma_Industries_vs_Chandan_Healthcare\" title=\"FAQs on Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare\">FAQs on Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/kilitch-drugs-vs-sudarshan-pharma-vs-chandan-healthcare\/#What_is_the_market_cap_difference_between_Kilitch_Drugs_India_Sudarshan_Pharma_Industries_and_Chandan_Healthcare\" title=\"What is the market cap difference between Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?\">What is the market cap difference between Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/kilitch-drugs-vs-sudarshan-pharma-vs-chandan-healthcare\/#What_are_the_PE_and_PB_ratios_of_Kilitch_Drugs_India_Sudarshan_Pharma_Industries_and_Chandan_Healthcare\" title=\"What are the PE and PB ratios of Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?\">What are the PE and PB ratios of Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/kilitch-drugs-vs-sudarshan-pharma-vs-chandan-healthcare\/#Which_of_the_three_has_the_highest_ROE\" title=\"Which of the three has the highest ROE?\">Which of the three has the highest ROE?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/kilitch-drugs-vs-sudarshan-pharma-vs-chandan-healthcare\/#Which_of_these_three_stocks_pays_the_highest_dividend_yield\" title=\"Which of these three stocks pays the highest dividend yield?\">Which of these three stocks pays the highest dividend yield?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/kilitch-drugs-vs-sudarshan-pharma-vs-chandan-healthcare\/#What_is_the_debt_to_equity_ratio_for_Kilitch_Drugs_India_Sudarshan_Pharma_Industries_and_Chandan_Healthcare\" title=\"What is the debt to equity ratio for Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?\">What is the debt to equity ratio for Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/kilitch-drugs-vs-sudarshan-pharma-vs-chandan-healthcare\/#What_were_the_latest_quarterly_revenue_and_net_profit_of_Kilitch_Drugs_India_Sudarshan_Pharma_Industries_and_Chandan_Healthcare\" title=\"What were the latest quarterly revenue and net profit of Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?\">What were the latest quarterly revenue and net profit of Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/kilitch-drugs-vs-sudarshan-pharma-vs-chandan-healthcare\/#Does_this_comparison_recommend_one_of_Kilitch_Drugs_India_Sudarshan_Pharma_Industries_and_Chandan_Healthcare\" title=\"Does this comparison recommend one of Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?\">Does this comparison recommend one of Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Kilitch_Drugs_India_Sudarshan_Pharma_Industries_and_Chandan_Healthcare_Company_Overview\"><\/span><strong>Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare: Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Kilitch Drugs (India)<\/strong> is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 852 crore, a return on equity of 10.79% and a book value of Rs 79.99 per share. Its quarterly revenue moved from Rs 45.70 crore in June 2025 to Rs 47.78 crore in June 2026, a change of +4.6%.<\/p>\n<p><strong>Sudarshan Pharma Industries<\/strong> is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 878 crore, a return on equity of 15.03% and a book value of Rs 6.67 per share. Its quarterly revenue moved from Rs 146.47 crore in June 2025 to Rs 175.64 crore in June 2026, a change of +19.9%.<\/p>\n<p><strong>Chandan Healthcare<\/strong> is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 581 crore, a return on equity of 11.34% and a book value of Rs 69.48 per share. Its quarterly revenue moved from Rs 68.77 crore in June 2025 to Rs 82.26 crore in June 2026, a change of +19.6%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Kilitch_Drugs_India_vs_Sudarshan_Pharma_Industries_vs_Chandan_Healthcare_Valuation_and_Profitability_Snapshot\"><\/span><strong>Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare: Valuation and Profitability Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/kilitch\/kilitch-drugs-(india)-ltd-share-price-today\">Kilitch Drugs (India)<\/a><\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/sudarshan\/sudarshan-pharma-industries-ltd-share-price-today\">Sudarshan Pharma Industries<\/a><\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/chandan\/chandan-healthcare-ltd-share-price-today\">Chandan Healthcare<\/a><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Market Cap (approx.)<\/td>\n<td>Rs 852 crore<\/td>\n<td>Rs 878 crore<\/td>\n<td>Rs 581 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>29.19<\/td>\n<td>35.15<\/td>\n<td>23.06<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>3.05<\/td>\n<td>5.27<\/td>\n<td>3.42<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity (ROE)<\/td>\n<td>10.79%<\/td>\n<td>15.03%<\/td>\n<td>11.34%<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM, Rs)<\/td>\n<td>8.35<\/td>\n<td>1.00<\/td>\n<td>10.30<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.00%<\/td>\n<td>0.00%<\/td>\n<td>0.00%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.32<\/td>\n<td>1.84<\/td>\n<td>0.31<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share (Rs)<\/td>\n<td>79.99<\/td>\n<td>6.67<\/td>\n<td>69.48<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Data<\/strong><\/a><\/p>\n<p>On valuation, Kilitch Drugs (India) trades at a PE of 29.19 and a PB of 3.05, Sudarshan Pharma Industries at a PE of 35.15 and a PB of 5.27, while Chandan Healthcare trades at a PE of 23.06 and a PB of 3.42. On return on equity, the three post 10.79%, 15.03% and 11.34% respectively, and on dividend yield they stand at 0.00%, 0.00% and 0.00%. Sudarshan Pharma Industries has the highest market capitalisation of the three at Rs 878 crore, while Chandan Healthcare has the lowest at Rs 581 crore. Sudarshan Pharma Industries has the highest PE ratio of the three at 35.15, while Chandan Healthcare has the lowest at 23.06. Sudarshan Pharma Industries has the highest return on equity of the three at 15.03%, while Kilitch Drugs (India) has the lowest at 10.79%. Sudarshan Pharma Industries has the highest debt to equity ratio of the three at 1.84, while Chandan Healthcare has the lowest at 0.31. Debt to equity is 0.32, 1.84 and 0.31 for the three respectively.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Kilitch_Drugs_India_vs_Sudarshan_Pharma_Industries_vs_Chandan_Healthcare_Latest_Quarterly_Results\"><\/span><strong>Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare: Latest Quarterly Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Company<\/th>\n<th>Latest Quarter Revenue<\/th>\n<th>Latest Quarter Net Profit<\/th>\n<th>YoY Change (Revenue)<\/th>\n<th>QoQ Change (Revenue)<\/th>\n<th>YoY Change (Net Profit)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Kilitch Drugs (India)<\/td>\n<td>Rs 47.78 crore<\/td>\n<td>Rs 1.97 crore<\/td>\n<td>+4.6%<\/td>\n<td>-47.0%<\/td>\n<td>-12.8%<\/td>\n<\/tr>\n<tr>\n<td>Sudarshan Pharma Industries<\/td>\n<td>Rs 175.64 crore<\/td>\n<td>Rs 5.61 crore<\/td>\n<td>+19.9%<\/td>\n<td>-22.0%<\/td>\n<td>+41.7%<\/td>\n<\/tr>\n<tr>\n<td>Chandan Healthcare<\/td>\n<td>Rs 82.26 crore<\/td>\n<td>Rs 7.91 crore<\/td>\n<td>+19.6%<\/td>\n<td>+6.2%<\/td>\n<td>+28.0%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Kilitch_Drugs_India_vs_Sudarshan_Pharma_Industries_vs_Chandan_Healthcare_Five-Quarter_Revenue_and_Net_Profit_Trend\"><\/span><strong>Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare: Five-Quarter Revenue and Net Profit Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare, which helps separate a one-quarter move from a steadier pattern.<\/p>\n<p><strong>Quarterly revenue (Rs crore)<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Kilitch Drugs (India)<\/th>\n<th>Sudarshan Pharma Industries<\/th>\n<th>Chandan Healthcare<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>June 2025<\/td>\n<td>Rs 45.70 crore<\/td>\n<td>Rs 146.47 crore<\/td>\n<td>Rs 68.77 crore<\/td>\n<\/tr>\n<tr>\n<td>September 2025<\/td>\n<td>Rs 55.58 crore<\/td>\n<td>Rs 170.73 crore<\/td>\n<td>Rs 68.74 crore<\/td>\n<\/tr>\n<tr>\n<td>December 2025<\/td>\n<td>Rs 55.34 crore<\/td>\n<td>Rs 169.53 crore<\/td>\n<td>Rs 65.78 crore<\/td>\n<\/tr>\n<tr>\n<td>March 2026<\/td>\n<td>Rs 90.09 crore<\/td>\n<td>Rs 225.05 crore<\/td>\n<td>Rs 77.43 crore<\/td>\n<\/tr>\n<tr>\n<td>June 2026<\/td>\n<td>Rs 47.78 crore<\/td>\n<td>Rs 175.64 crore<\/td>\n<td>Rs 82.26 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Quarterly net profit (Rs crore)<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Kilitch Drugs (India)<\/th>\n<th>Sudarshan Pharma Industries<\/th>\n<th>Chandan Healthcare<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>June 2025<\/td>\n<td>Rs 2.26 crore<\/td>\n<td>Rs 3.96 crore<\/td>\n<td>Rs 6.18 crore<\/td>\n<\/tr>\n<tr>\n<td>September 2025<\/td>\n<td>Rs 8.04 crore<\/td>\n<td>Rs 3.87 crore<\/td>\n<td>Rs 8.25 crore<\/td>\n<\/tr>\n<tr>\n<td>December 2025<\/td>\n<td>Rs 4.32 crore<\/td>\n<td>Rs 4.15 crore<\/td>\n<td>Rs 5.03 crore<\/td>\n<\/tr>\n<tr>\n<td>March 2026<\/td>\n<td>Rs 14.88 crore<\/td>\n<td>Rs 11.39 crore<\/td>\n<td>Rs 4.94 crore<\/td>\n<\/tr>\n<tr>\n<td>June 2026<\/td>\n<td>Rs 1.97 crore<\/td>\n<td>Rs 5.61 crore<\/td>\n<td>Rs 7.91 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Kilitch Drugs (India) reported revenue of Rs 45.70 crore in June 2025 and Rs 47.78 crore in June 2026, a change of +4.6% across the period. Its highest quarterly revenue in this window was Rs 90.09 crore in March 2026. Net profit stood at Rs 1.97 crore in June 2026, which is a net profit margin of 4.12%.<\/p>\n<p>Sudarshan Pharma Industries reported revenue of Rs 146.47 crore in June 2025 and Rs 175.64 crore in June 2026, a change of +19.9% across the period. Its highest quarterly revenue in this window was Rs 225.05 crore in March 2026. Net profit stood at Rs 5.61 crore in June 2026, which is a net profit margin of 3.19%.<\/p>\n<p>Chandan Healthcare reported revenue of Rs 68.77 crore in June 2025 and Rs 82.26 crore in June 2026, a change of +19.6% across the period. Its highest quarterly revenue in this window was Rs 82.26 crore in June 2026. Net profit stood at Rs 7.91 crore in June 2026, which is a net profit margin of 9.62%.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare live prices.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Should_Investors_Look_at_Beyond_These_Numbers\"><\/span><strong>What Should Investors Look at Beyond These Numbers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Beyond the metrics above, investors comparing these three pharma and healthcare names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as regulatory approvals, export orders, raw material costs and working capital needs. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.<\/p>\n<p>It also helps to read the latest quarterly filings and investor presentations of Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare highlights how differently three companies in the same pharma and healthcare segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information as of October 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Kilitch_Drugs_India_vs_Sudarshan_Pharma_Industries_vs_Chandan_Healthcare\"><\/span><strong>FAQs on Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_market_cap_difference_between_Kilitch_Drugs_India_Sudarshan_Pharma_Industries_and_Chandan_Healthcare\"><\/span><strong>What is the market cap difference between Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of October 2026, Kilitch Drugs (India) has a market cap of approximately Rs 852 crore, Sudarshan Pharma Industries is at approximately Rs 878 crore, and Chandan Healthcare is at approximately Rs 581 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_PE_and_PB_ratios_of_Kilitch_Drugs_India_Sudarshan_Pharma_Industries_and_Chandan_Healthcare\"><\/span><strong>What are the PE and PB ratios of Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of October 2026, the PE ratios stand at 29.19, 35.15 and 23.06 respectively, and the price to book ratios stand at 3.05, 5.27 and 3.42 respectively.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_the_three_has_the_highest_ROE\"><\/span><strong>Which of the three has the highest ROE?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare post ROE of 10.79%, 15.03% and 11.34% respectively as of October 2026. Sudarshan Pharma Industries has the highest return on equity of the three at 15.03%, while Kilitch Drugs (India) has the lowest at 10.79%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_these_three_stocks_pays_the_highest_dividend_yield\"><\/span><strong>Which of these three stocks pays the highest dividend yield?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare carry dividend yields of 0.00%, 0.00% and 0.00% respectively.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_debt_to_equity_ratio_for_Kilitch_Drugs_India_Sudarshan_Pharma_Industries_and_Chandan_Healthcare\"><\/span><strong>What is the debt to equity ratio for Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Kilitch Drugs (India) carries a debt to equity of 0.32, Sudarshan Pharma Industries of 1.84, and Chandan Healthcare of 0.31.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_latest_quarterly_revenue_and_net_profit_of_Kilitch_Drugs_India_Sudarshan_Pharma_Industries_and_Chandan_Healthcare\"><\/span><strong>What were the latest quarterly revenue and net profit of Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> For Q1 FY27 (quarter ended June 2026), Kilitch Drugs (India) reported revenue of Rs 47.78 crore and net profit of Rs 1.97 crore, Sudarshan Pharma Industries reported revenue of Rs 175.64 crore and net profit of Rs 5.61 crore, and Chandan Healthcare reported revenue of Rs 82.26 crore and net profit of Rs 7.91 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Does_this_comparison_recommend_one_of_Kilitch_Drugs_India_Sudarshan_Pharma_Industries_and_Chandan_Healthcare\"><\/span><strong>Does this comparison recommend one of Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor&#8217;s own criteria and research.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the market cap difference between Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of October 2026, Kilitch Drugs (India) has a market cap of approximately Rs 852 crore, Sudarshan Pharma Industries is at approximately Rs 878 crore, and Chandan Healthcare is at approximately Rs 581 crore.\"}},{\"@type\":\"Question\",\"name\":\"What are the PE and PB ratios of Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of October 2026, the PE ratios stand at 29.19, 35.15 and 23.06 respectively, and the price to book ratios stand at 3.05, 5.27 and 3.42 respectively.\"}},{\"@type\":\"Question\",\"name\":\"Which of the three has the highest ROE?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare post ROE of 10.79%, 15.03% and 11.34% respectively as of October 2026. Sudarshan Pharma Industries has the highest return on equity of the three at 15.03%, while Kilitch Drugs (India) has the lowest at 10.79%.\"}},{\"@type\":\"Question\",\"name\":\"Which of these three stocks pays the highest dividend yield?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare carry dividend yields of 0.00%, 0.00% and 0.00% respectively.\"}},{\"@type\":\"Question\",\"name\":\"What is the debt to equity ratio for Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Kilitch Drugs (India) carries a debt to equity of 0.32, Sudarshan Pharma Industries of 1.84, and Chandan Healthcare of 0.31.\"}},{\"@type\":\"Question\",\"name\":\"What were the latest quarterly revenue and net profit of Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"For Q1 FY27 (quarter ended June 2026), Kilitch Drugs (India) reported revenue of Rs 47.78 crore and net profit of Rs 1.97 crore, Sudarshan Pharma Industries reported revenue of Rs 175.64 crore and net profit of Rs 5.61 crore, and Chandan Healthcare reported revenue of Rs 82.26 crore and net profit of Rs 7.91 crore.\"}},{\"@type\":\"Question\",\"name\":\"Does this comparison recommend one of Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare compared on market cap, PE, ROE and quarterly results, as of October 2026.<\/p>\n","protected":false},"author":28,"featured_media":303312,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[11016,1019],"class_list":["post-303313","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-pharma-and-healthcare","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["303312"],"rank_math_title":["Kilitch Drugs vs Sudarshan Pharma vs Chandan Healthcare"],"rank_math_description":["Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare compared on market cap, PE, ROE and quarterly results, as of October 2026."],"rank_math_focus_keyword":["Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/kilitch-drugs-vs-sudarshan-pharma-vs-chandan-healthcare-which-stock-should-you.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/303313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=303313"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/303313\/revisions"}],"predecessor-version":[{"id":303314,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/303313\/revisions\/303314"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/303312"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=303313"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=303313"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=303313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}